Effectiveness And Safety Of Dalteparin In Patients With Acute Coronary Syndromes Without ST Elevations In Clinical Practice
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
To collect data on safety and effectiveness of dalteparin in the management of non-ST segment
elevated acute coronary syndromes in nursing home patients who will be treated conservatively
(without percutaneous corornary intervention [PCI] or coronary artery bypass graft [CABG]
within 48 hours).